Dermata Therapeutics Price To Sales Ratio Over Time
| DRMA Stock | USD 1.13 0.03 2.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dermata Therapeutics Performance and Dermata Therapeutics Correlation. Dermata |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Sales Ratio Analysis
Compare Dermata Therapeutics and related stocks such as Zura Bio Limited, Phio Pharmaceuticals Corp, and Sonnet Biotherapeutics Price To Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PHIO | 122 | 122 | 122 | 85.3011 | 495 | 733 | 253 | 836 | 16.8071 | 206 | 206 | 206 | 206 | 186 | 275 |
| SONN | 0.9898 | 0.9898 | 0.9898 | 17.1668 | 0.9898 | 4.2939 | 1.748 | 1.2796 | 1.1797 | 246 | 246 | 146 | 161 | 1.1797 | 1.12 |
| ATNF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CDIO | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 3.4 K | 1.9 K | 1.8 K |
| WINT | 1.2 K | 1.3 K | 8.5 K | 5.8 K | 627 | 381 | 91.7299 | 52.332 | 226 | 580 | 580 | 580 | 580 | 666 | 633 |
| ENSC | 139 | 139 | 139 | 139 | 139 | 139 | 139 | 139 | 139 | 139 | 49.8788 | 26.8386 | 0.6418 | 1.0759 | 1.02 |
| ZVSA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| REVB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CYTO | 71.3374 | 71.3374 | 71.3374 | 71.3374 | 71.3374 | (4.7 K) | (181) | 164 | 11.2696 | (163) | 79.9759 | 343 | 13.3565 | 12.02 | 12.62 |
| IMMX | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3) | (0.32) |
| HEPA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Dermata Therapeutics and related stocks such as Zura Bio Limited, Phio Pharmaceuticals Corp, and Sonnet Biotherapeutics Price To Sales Ratio description
Price to Sales Ratio is figured by comparing Dermata Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Dermata Therapeutics sales, a figure that is much harder to manipulate than other Dermata Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.My Equities
My Current Equities and Potential Positions
| Dermata Therapeutics | DRMA |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.13
Check out Dermata Therapeutics Performance and Dermata Therapeutics Correlation. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Dermata Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.